Inozyme

Corporate Profile

Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical dedicated to developing novel treatments for rare diseases associated with the PPi-Adenosine Axis, a critical pathway regulating mineralization and vascular health. Disruptions in this pathway lead to severe conditions such as ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis and ossification of the posterior longitudinal ligament (OPLL). Inozyme’s lead product candidate, INZ-701, is an enzyme replacement therapy (ERT) designed to correct these disruptions. By addressing pathologic mineralization and intimal proliferation, INZ-701 targets the underlying causes of significant morbidity and mortality in these devastating diseases. INZ-701 is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.